Clinical and pharmacoeconomical effectiveness of fabomotizol in the treatment of arterial hypertension with meteosensitivity
To study the clinical and pharmacoeconomical effectiveness of the drug fabomotizol in the complex therapy of patients with arterial hypertension with meteosensitivity, the study involved patients with hypertension with meteosensitivity of working age, subgroup IA (n = 51) – patients with hypertension with meteosensitivity who took hypotensive therapy according to the clinical recommendations of the Russian Society of Cardiology (RKO,2019) and additionally took anxiolytic 50 mg per day 3 days before the change in weather conditions, Subgroup IB (n = 51) – weather-sensitive and group II (n = 96) – non-weather-sensitive, were treated according to the treatment protocol. During the follow-up period, the number of additional visits to the doctor of AH patients with meteosensitivity in the IA subgroup decreased by 64.6 % (p = 0.001), in the IB subgroup – by 27,2 % (p = 0.22) and in the II group-by 44,6 % (p = 0,015); the number of emergency calls by 25,5 % (p = 0.033), by 7.8 % (p = 0.34) and by 15,6 % (p = 0.044), respectively, the target levels of SAD/DAD were achieved in 72,7 % / 68.6 %; 45,1 % / 1,8 % and 64,1 % / 69.5 %, respectively. The results of the cost – effectiveness (CER) calculation with the additional use of fabomotizol in patients with hypertension are economically justified and show a positive dynamics of clinical data with the achievement of the target blood pressure level.
Kildebekova R.N., Vardikyan A.G., Bikkinina G.M., Kaybishev V.T., Sayachov R.F., Fedotov A.L. 2021 Clinical and pharmacoeconomical effectiveness of fabomotizol in the treatment of arterial hypertension with meteosensitivity. Challenges in Modern Medicine. 44 (3): 296–304 (in Russian). DOI: 10.52575/2687-0940-2021-44-3-296-304
While nobody left any comments to this publication.
You can be first.
Vdovichenko V.P., Goncharuk V.V, Korshak T.A., Bronskaya G.M. 2018. Ingibitory` APF: edinstvo v mnogoobrazii [ACE inhibitors: unity in diversity]. Medicinskie novosti. 1: 73–76.
Grigor`ev K.I., Povazhnaya E.L. 2018. Problema povy`shennoj meteochuvstvitel`nosti u detej i podrostkov [The problem of increased meteosensitivity in children and adolescents]. Rossijskij vestnik perinatologii i pediatrii. 63 (3): 84–90. doi.org/10.21508/1027-4065-2018-63-3-84-90.
Drapkina O.M., Eliashevich S.O. Shepel R.N. 2016. Ozhirenie kak faktor riska xronicheskix neinfekcionny`x zabolevanij [Obesity as a risk factor for chronic non-communicable diseases]. Rossijskij kardiologicheskij zhurnal 6 (134): 73–79. doi.org/10.15829/1560-4071-2016-6-73-79.
Razumova F.G., Kamilov F.X., Kapuler O.M., Mufazalova N.A. 2014. K farmakologii Afobazola [To pharmacology of afobazole]. Fundamental`ny`e issledovaniya. 7 (4): 848–855.
Reshet`ko O.V, Lucevich K.A. 2015. Farmakoe`konomika kak instrument klinicheskoj farmakologii dlya optimizacii farmakoterapii [Pharmacoeconomics as an instrument of clinical pharmacology for optimization of pharmacotherapy (review)]. Vedomosti nauchnogo centra e`kspertizy` sredstv medicinskogo primeneniya. 4: 54–57.
Svishhenko E.P., Gulkevich O.V. 2014. Opy`t primeneniya preparata Afobazol u pacientov s gipertonicheskoj bolezn`yu i panicheskimi atakami [Experience of using the drug Afobazol in patients with hypertension and panic attacks]. Psixiatriya. Psixicheskie rasstrojstva v obshhej medicine. 01:
56–60.
Smirnov M.D., Barinova I.V., Blankova Z.N., Ageeva N.V., Muxina A.A., Borodulina I.V., Marfina T.V., Badalov N.G., Ageeva F.T. 2018. Meteochuvstvitel`nost` u bol`ny`x arterial`noj gipertoniej: proyavleniya i prediktory` [Meteosensitivity in patients with arterial hypertension: manifestations and predictors]. Kardiologicheskij vestnik. 13 (4): 23–29. DOI: 10.17116/Cardiobulletin20181304123.
Chazova I.E., Zhernakova Yu.V. 2019. Klinicheskie rekomendacii. Diagnostika i lechenie arterial`noj gipertonii [Clinical guidelines. Diagnosis and treatment of arterial hypertension]. Sistemny`e gipertenzii. 16 (1): 6–31.
Chumakova E.A., Gaponova N.I., Berezina T.N. 2014. Ocenka e`ffektivnosti primeneniya terapii Afobazolom v kompleksnom lechenii bol`ny`x arterial`noj gipertenziej [Afobazole effectiveness in the complex treatment of patients with arterial hypertension]. Rossijskij kardiologicheskij zhurnal. 2 (106): 89–95. doi.org/10.15829/1560-4071-2014-2-8.
Azcárate T., Mendoza B. 2017. Influence of geomagnetic activity and atmospheric pressure in hypertensive adults. Int. J. Biometeorol. 61 (9): 1585–1592.
Mozaffarian D., Benjamin E.J., Go A.S., Arnett D.K., Blaha M.J., Cushman M., Das S.R., de Rerranti S., Despres J.P., Fullerton H.J., Howard V.J., Huffman M.D., Isasi C.R., Jimenez M.C., Judd S.E., Kissela B.M., Lichtman J.H., Lisabeth L.D., Liu S., Mackey R.H., Magid D.J., McGuire D.K., Mohier E.R. 3rd, Moy C.S., Muntner P., Mussolino M.E., Nasir K., Neumar R.W., Nichol G., Palaniappan L., Pandey D.K., Reeves M.J., Rodriguez C.J., Rosamond W., Sorlie P.D., Stein J., Towfighi A., Turan T.N., Virani S.S., Woo D., Yeh R.W., Turner M.B. 2016. Heart disease and stroke statistics-2016 update a report from the American Heart Association. Circulation. 133 (4): 38–360. DOI:10.1161/CIR.0000000000000350.
Tsai T., Kroehl M.E., Smith S.M., Thompson A.M., Dai I.Y., Trinkley K.E. 2017. Efficacy and safety of twice- vs once-daily dosing of lisinopril for hypertension. J. Clin. Hypertens. (Greenwich). 19 (9): 868–873.
Turner J.M., Kodali R. 2020. Should Angiotensin-Converting Enzyme Inhibitors ever Be Used for the Management of Hypertension? Curr. Cardiol. Rep. 22 (9): 95.
Williams B., Mancia G., Spiering W., Agabiti Rosei E., Azizi M., Burnier M. Clement D.L., Coca A., de Simone G., Dominiczak A., Kahan T., Mahfound F., Redon J., Ruilope L., Zanchetti A., Kerins M., Kjeldsen S.E., Kreutz R., Laurent S., Lip G.Y.H., McManus R., Narkiewicz K., Ruschitzka F., Schmieder R.E., Shlyakhto E., Tsioufis C., Aboyans V., Desormais I. 2018. ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension [published correction appears in J. Hypertens.]. 36 (10): 1953–2041. DOI:10.1097/HJH.0000000000001940.